社團法人台灣腦中風學會
Taiwan Stroke Society

台灣腦中風學會 2026 年會

NOV. 13-15

台大國際會議中心3-4F



大會手冊

【攜手共創腦中風防治新里程】
2026 台灣腦中風學會年會 理事長邀請函

各位尊敬的會員醫師、專家學者與醫療夥伴，您好：

歲月流轉，一年一度屬於全體腦中風醫療團隊的盛會—2026台灣腦中風學會年會，即將於11月13日至15日在台大國際會議中心隆重登場！在此，我謹代表學會向長期於臨床與研究第一線默默耕耘的各位致上最深敬意，並誠摯邀請大家撥冗蒞臨，共襄盛舉。今年年會以「前瞻、創新、跨域、實踐」為主軸，精心籌備了多樣化且具深度的學術與實務課程：

一、國際巨擘雲集，聚焦前沿醫學

我們特別邀請四位國際重量級Keynote Speakers帶來最新突破：

- Mike Sharma教授：剖析新一代抗凝血治療Factor XI Inhibitors的最新臨床試驗與發展趨勢。
- Joanna Wardlaw教授：分享腦小血管疾病（CSVD）領域的國際最新研究成果。
- Hugues Chabriat教授：深入探討CADASIL與遺傳性腦小血管疾病的臨床新觀點。
- Bernard Yan教授：分享急性缺血性腦中風血管內治療（EVT）的最新進展與未來方向。

此外，更規劃了兩場深度互動的特色工作坊：由Henry Ma教授領軍的Young Stroke Physicians Workshop（扶植年輕世代拓展國際視野），以及Joanna Wardlaw & CSVD Workshop（提供專家交流與跨國合作平台）。

二、政策對談與實務挑戰，鏈結醫療生態圈

特別提醒大家，11月13日（週五）下午將舉辦重磅的「腦中風區域聯防官署對談」，邀集衛生福利部官員與產官學界專家，共同探討區域聯防體系的優化與落地實踐；同期還有熱血沸騰的「案例挑戰競賽」，邀請各院精英切磋臨床實戰智慧！

三、首次重磅推出：中正紀念堂「Run for Stroke」慢跑活動

除了豐富的學術饗宴，學會今年更創下首例，將於中正紀念堂舉辦首屆「Run for Stroke慢跑活動」！讓我們暫時放下診間與病房的忙碌，穿上跑鞋，共同為腦中風健康平權與預訪宣導而跑，用汗水與活力展現我們守護國人腦血管健康的決心。

期待在今年秋天的年會中，與各位新老朋友相聚，交流新知、凝聚共識，攜手推動台灣腦中風醫療再創新高高峰！

敬祝　醫安 順心

陳 龍 敬邀

社團法人台灣腦中風學會第十六屆理事長

2026年11月

大會主席的話

2026年台灣腦中風學會年會將於本年11月13-15日於台大醫院國際會議中心舉行，值此急重症醫療為大家所關注之際，但又面對第一線相關急重症醫療人力的短缺，這其中急性中風的診療無疑是重中之重，這需要跨科部團隊的緊密合作，結合院前消防救護、急診第一時間處置、加護病房的照護等。如何一方面讓所有中風學會會員們吸收最新知識，又能有相對策略降低臨床負荷壓力與提升效率，這是本年會希望能對所有參與者提供一些助益。今年的節目邀請了多位國際知名學者講述腦中風治療的最新進展，同時也邀請了官署們與大家雙向交流，內容精采，還安排了中正紀念堂晨跑活動，值得大家撥冗參加，竭誠歡迎您的蒞臨。

謹祝 大會成功

鄭建興 敬邀

台大醫院神經部主任、台灣神經學學會理事長

2026年11月

目錄

大會總表 01
場地配置圖 03
會議議程 05
午餐議程 11
Keynote Speech 15
壁報論文總覽 21

大會總表

NOV.13 FRI.

TIME	TOPIC
	Venue 301
14:30-15:50	區域聯防議題
15:50-16:10	Break
16:10-16:30	台灣急性中風處置資源地圖
16:30-16:50	健保署腦中風轉診平台優化
16:50-17:20	官署對話
18:30-20:30	Resident Case Sharing (喜來登)

NOV.14 SAT.

TIME	TOPIC	
	Main Hall (401)	SubHall (301)
09:00-10:30	Taiwan - Korea Stroke Research Forum	Emerging Risk Factors in Stroke
10:30-11:00	Break	
11:00-11:40	Keynote 1 : Mike Sharma (Factor XIa inhibitors)	同步視訊401
11:40-12:05	Korea - Japan - Taiwan Moyamoya Consensus	
12:05-13:30	Lunch	
13:30-15:00	Precision Pharmacology in Stroke	Heart - Brain Interaction
15:00-15:30	Break	
15:30-16:10	Keynote 2 : Joanna Wardlaw (CSVD)	同步視訊401
16:10-16:50	Keynote 3 : Hugues Chabriat (CADASIL)	
16:50-17:00	Break	
17:00-17:25	Best Paper Award	Post - Stroke Disability
17:25-18:00	Poster Session	
18:30-	Gala Dinner @1F, NTUH International Convention Center	

Meet the Professor (403)
09:00-10:30 Henry Ma & Young stroke physicians


TIME	TOPIC
	腦中風個管師課程暨認證 (402AB)
09:00-09:30	腦中風治療新進展(I) 急性中風處置
09:30-10:30	血脂管理： 打造腦血管防護網
10:30-11:00	Break
11:00-12:00	戒菸防中風 守護腦血管
12:00-13:30	Lunch
13:30-15:00	AI來助攻： 智慧醫療新體驗
15:00-15:30	Break
15:30-16:00	腦中風治療新進展(II) 次級中風預防
16:00-16:30	輔具怎麼選？ 找回生活自主力
16:30-17:30	動起來! 腦中風預防的運動處方 402CD
17:30-18:00	認證考試

NOV.15 SUN.

TIME	TOPIC	
	Main Hall (401)	SubHall (301)
08:30-09:10	官署對談	ICH Diagnosis & Treatment
09:10-10:10	Advances in Stroke Neuroimaging	
10:10-10:30	Break	
10:30-11:10	Keynote 4 : Bernard Yan (EVT)	同步視訊401
11:10-11:30	許重義教授論文講座	
11:30-12:00	會員大會	
12:00-13:30	Lunch	
13:30-15:00	CME : Stroke Guideline Update	中風王
15:00-15:30		

腦中風個管師課程暨認證 (402AB)		Meet the Professor (403)
08:30-10:00 個管師實務分享課程	13:30-15:30 超音波認證	08:30-10:00 Joanna Wardlaw & CSVD Workshop


場地配置



B15 & B16｜裕利

A01｜吉生　**A02**｜施維雅

A03｜麗寶　**A04**｜艾伯維



B01｜聯銘盛
B02｜諾華
B03｜東生華
B04 & B05｜大塚
B06｜企建
B07｜芝利
B08｜禾熠
B09｜歐嘉隆
B10｜賽諾菲
B11｜第一三共
B12｜百靈佳
B13｜佑康
B14｜暉致

會議議程

NOV. 13 FRI. Venue 301

TIME	TOPIC	SPEAKER	MODERATOR
14:30-14:50	區域聯防議題1(北區)	湯頌君 Sung-Chun Tang	陳右緯 Yu-Wei Chen
14:50-15:10	區域聯防議題2(南區)	黃彥筑 Yen-Chu Huang	
15:10-15:30	區域聯防議題3(區域醫院)	黃韋綾 Wei-Ling Huang	嚴寶勝 Pao-Sheng Yen
15:30-15:50	區域聯防議題4(偏鄉)	胡智銘 Chin-Ming Hu	
15:50-16:10	Break		
16:10-16:30	台灣急性中風處置資源地圖	宋碧姍 Pi-Shan Sung	邱弘毅 Hung-Yi Chiou
16:30-16:50	健保署腦中風轉診平台優化	陳　龍 Lung Chan	黃金安 Jin-An Huang
16:50-17:20	官署對話	顏家瑞 副署長 健保署 陳潤秋 局長 新北市政府衛生局 黃建華 局長 台北市政府衛生局	陳　龍 Lung Chan 連立明 Li-Ming Lien
18:30-20:30	Resident Case Sharing (喜來登)		

NOV. 14 SAT. Main Hall (401)

TIME	TOPIC / SESSION	SPEAKER	MODERATOR
Taiwan-Korea Stroke Research Forum			
08:55-09:00	Opening		陳 龍 Lung Chan
09:00-09:20	From Routine Images to Shared Evidence: The CRCS-K Imaging Repository and Prospects for Taiwan–Korea Collaboration	**Beom Joon Kim** South Korea	**Keun-Sik Hong** South Korea
09:20-09:40	The impact of blood pressure variability and cerebral autoregulation on cerebral small vessel disease and cognitive function	紀乃方 Nai-Fang Chi	劉濟弘 Chi-Hung Liu
09:40-10:00	Thrombus Ultrastructure: From Electron Microscopy to Imaging and Clinical Implications	**Hyungjong Park** South Korea	**Hyo Suk Nam** South Korea
10:00-10:20	Interleukin-6 is associated with reperfusion injury and poor functional outcome after endovascular thrombectomy for acute ischemic stroke	葉馨喬 Shin-Joe Yeh	趙雅琴 A-Ching Chao
10:30-11:00	Break		
Keynote 1			
11:00-11:40	Game changer: Factor XI Inhibitors for Secondary Prevention of Non-Cardioembolic Ischemic Stroke	**Mike Sharma** Canada	李怡慧 I-Hui Lee
Korea-Japan-Taiwan Moyamoya Consensus			
11:40-12:05	Clinical Practice Guidelines for Moyamoya Disease in Asia	**JinMan Jung** South Korea	郭夢菲 Meng-Fai Kuo
12:05-13:30	Lunch		
Precision Pharmacology in Stroke			
13:30-13:50	CYP2C19 in P2Y12 inhibitors	廖年晨 Nien-Chen Liao	陳柏霖 Po-Lin Chen 蔡力凱 Li-Kai Tsai
13:50-14:10	IVT in DOAC <24h	林欣儀 Shin-Yi Lin	
14:10-14:30	Early antithrombotics after IVT	陳志昊 Chih-Hao Chen	
14:30-14:50	Antithrombotics in ATT users	宋碧姍 Pi-Shan Sung	
15:00-15:30	Break		
Keynote 2			
15:30-16:10	Cerebral Small Vessel Disease: Recent Advances and Implications for Treatment	**Joanna Wardlaw** United Kingdom	鍾芷萍 Chih-Ping Chung
Keynote 3			
16:10-16:50	CADASIL as a Prototype for Precision Clinical Trials in Cerebral Small Vessel Disease	**Hugues Chabriat** France	鄭建興 Jiann-Shing Jeng
16:50-17:00	Break		
Poster Session			
17:00-17:25	Best Paper Award		陳 龍 Lung Chan
17:25-18:00	Poster Session		湯頌君 Sung-Chun Tang

會議議程

NOV. 14 SAT. Venue 301

TIME	TOPIC	SPEAKER
Emerging Risk Factors in Stroke | 謝鎮陽 Cheng-Yang Hsieh　彭家勛 Gilia-Sheun Peng		
09:00-09:30	Move It or Lose It? Exercise in Secondary Stroke Prevention	王思恒 Szu-Heng Wang
09:30-10:00	Beyond BMI : The Weight of Evidence in Stroke Seconary Prevention	陳昱彰 Yu-Chang Chen
10:00-10:30	Lp(a) and ApoB in Stroke Prevention : The Risk Factors We Can No Longer Ignore	劉秉彥 Ping-Yen Liu
10:30-11:00	Break	
11:00-12:05	同步視訊401	
12:05-13:30	Lunch	
Heart-Brain Interaction | 李宗海 Tsong-Hai Lee　林瑞泰 Ruey-Tay Lin		
13:30-13:50	Heart-Brain Interaction in Stroke	王其聖 Chi-Sheng Wang
13:50-14:10	Interactions Between Atrial Cardiomyopathy, Subclinical Atrial Fibrillation, and Ischemic Stroke	趙子凡 Tze-Fan Chao
14:10-14:30	Structural Cardiac Imaging in Stroke, from Echocardiography to MRI	郭　泠 Ling Kuo
14:30-14:50	PFO and Stroke : Classification, Characteristics, and Interventional Treatment	林明志 Ming-Chih Lin
15:00-15:30	Break	
15:30-16:50	同步視訊401	
16:50-17:00	Break	
Post-stroke disability | 胡朝榮 Chaur-Jong Hu　宋昇峯 Sheng-Feng Sung		
17:00-17:20	Thinking After Stroke : Cognitive Impairment and Recovery	陳嘉泓 Jia-Hung Chen
17:20-17:40	Swallowing Matters : Dysphagia and Its Clinical Impact	蘇慧真 Hui-Chen Su
17:40-18:00	Moving Again : Motor Recovery and Spasticity Management	張庭瑜 Ting-Yu Chang

NOV.14 SAT. ROOM 402AB

TIME	TOPIC	SPEAKER	MODERATOR
腦中風治療新進展(I) 急性中風處置			
09:00-09:30	腦中風治療新進展(I) 急性中風處置	周鴻杰 Hong-Jie Jhou	傅維仁 Wei-Ren Fu
09:30-10:00	中風二級預防的血脂治療新趨勢	吳宜真 Yee-Jen Wu	林浚仁 Chun-Jen Lin
10:00-10:30	高血脂醫療給付改善方案－執行經驗分享	鍾岱均 Tai-Chun Chung	
10:30-11:00	Break		
戒菸防中風,守護腦血管			
11:00-11:30	腦中風再發預防： 全人全團隊之戒菸治療服務	江建勰 Chien-Hsieh Chiang	林宏昇 Hung-Sheng Lin
11:30-12:00	Panel discussion : 如何整合戒菸服務及中風個案管理		
12:00-13:30	Lunch		
AI來助攻：智慧醫療新體驗			
13:30-14:20	AI 在醫療與個案管理的發展	周安國 An-Kuo Chou	林雅如 Ya-Ju Lin
14:20-15:00	AI在個案管理的實務應用	鍾雨珍 Yu-Chen Chung	
15:00-15:30	Break		
腦中風治療新進展(II) 次級中風預防			
15:30-16:00	腦中風治療新進展(II) 次級中風預防	郭書帆 Shu-Fan Kuo	林清煌 Ching-Huang Lin
輔具介紹			
16:00-16:30	輔具怎麼選？找回生活自主力	林立峯 Li-Fong Lin	陳俊鴻 Chun-Hung Chen
認證考試			
17:30-18:00	認證考試		顏尚易 Shang-Yih Yen

NOV.14 SAT. ROOM 402CD

TIME	TOPIC	SPEAKER
健康運動		
16:30-17:30	動起來！腦中風預防的運動處方	陳冠吉 Guan-Ji Chen

NOV.14 SAT. ROOM 403

TIME	TOPIC	SPEAKER	MODERATOR
09:00-10:30	Henry Ma & Young Stroke Physicians	Henry Ma Australia	張育銘 Yu-Ming Chang

會議議程

NOV. 15 SUN. | Main Hall (401)

TIME	TOPIC	SPEAKER
官署對談｜陳　龍 Lung Chan　**連立明** Li-Ming Lien		
08:30-09:10	官署對談	
Advances in Stroke Neuroimaging ｜張豐基 Feng-Chi Chang　**李　孟** Meng Lee		
09:10-09:30	Molecular Imaging Signatures of Cerebral Amyloid Angiopathy	**蔡欣熹** Hsin-Hsi Tsai
09:30-09:50	White Matter Structural Changes during Acute Ischemic Stroke	**魏怡嘉** Yi-Chia Wei
09:50-10:10	Distinct Spatiotemporal Patterns of White Matter Hyperintensity Progression	**Dong-Eog Kim** South Korea
10:10-10:30	Break	
Keynote 4 ｜陳　龍 Lung Chan		
10:30-11:10	Endovascular thrombectomy - state of the art in 2026	**Bernard Yan** Australia
許重義教授論文講座 ｜李俊泰 Jiunn-Tay Lee		
11:10-11:30	Seeing the Vessels, Understanding the Brain : My Two-Decade Journey in Cerebrovascular Research	**鍾芷萍** Chih-Ping Chung
11:30-12:00	會員大會	
12:00-13:30	Lunch	
CME ｜黃虹瑜 Hung-Yu Huang		
13:30-14:00	急性中風處置 Acute Stroke Management	**謝沛峰** Pei Feng Hsieh
14:00-14:30	抗血栓藥物與中風次級預防 Antithrombotic Therapy for Secondary Stroke Prevention	**歐陽彣昱** Wen-Yu Ou Yang
14:30-15:00	心血管危險因子與中風次級預防 Vascular Risk Factor Control for Secondary Stroke Prevention	**許博荏** Po-Jen Hsu

NOV. 15 SUN. Venue 301

TIME	TOPIC	SPEAKER
ICH Diagnosis & Treatment ｜周兆亮 Chao-Liang Chou　黃博浩 Po-Hao Huang		
08:30-09:00	Case Selection and Experience of Robotic ICH Aspiration	陳春忠 Chun-Chung Chen
09:00-09:30	Endoscopic Experience in ICH Operation	陳睿生 Jui-Sheng Chen
09:30-10:00	Etiological Work Up in Intracerebral Haemorrhage	Marco Pasi France
10:10-10:30	Break	
10:30-12:00	同步視訊 401	
12:00-13:30	Lunch	
13:30-15:30	中風王	

NOV. 15 SUN. ROOM 402AB

TIME	TOPIC	SPEAKER	MODERATOR
個管師實務分享課程			
08:30-09:15	個案管理系統建置與實務分享	黃光雨 Kuang-Yu Huang	巫錫霖 Shey-Lin Wu
09:15-10:00	腦中風疾病照護認證實務分享	蕭碧如 Pi-Ju Hsiao	
超音波認證			
13:30-14:00	穿顱超音波中線偏移與腦疝脫檢查	郭曄嶸 Yeh-Jung Kuo	林信光 Shin-Kuang Lin
14:00-14:30	顱內血管血流基礎評估	葉馨喬 Shin-Joe Yeh	
14:30-15:00	栓子連續偵測	紀乃方 Nai-Fang Chi	葉守正 Shoou-Jeng Yeh
15:00-15:30	健保申報建議報告格式及注意事項	劉濟弘 Chi-Hung Liu	

NOV. 15 SUN. ROOM 403

TIME	TOPIC	SPEAKER	MODERATOR
08:30-10:00	Joanna Wardlaw & CSVD Workshop	Joanna Wardlaw United Kingdom	王淳民 Chun-Min Wang

午餐議程

NOV. 14 SAT.

TIME	TOPIC	SPEAKER	MODERATOR
		台灣第一三共股份有限公司 Venue 301	
12:10-12:20	Opening		趙雅琴 醫師 高醫附醫
12:20-13:00	Managing High-Risk Patients: Non-Statin Options for Cardiovascular Protection	紀乃方 醫師 臺北榮總	趙雅琴 醫師 高醫附醫
13:00-13:20	Discussion and QA	趙雅琴 醫師 高醫附醫 鍾芷萍 醫師 臺北榮總	
13:20-13:30	Closing Remarks		趙雅琴 醫師 高醫附醫
		台灣大塚製藥股份有限公司 Main Hall (401)	
12:10-12:15	Opening		傅維仁 醫師 馬偕醫院
12:15-12:45	Real-world Experience with Cilostazol-based Strategies in SVD	葉馨喬 醫師 台大醫院	傅維仁 醫師 馬偕醫院
12:45-13:15	Real-world Experience With Cilostazol-based DAPT In ICAS	吳俞萱 醫師 台中榮總	巫錫霖 醫師 彰化秀傳
13:15-13:30	Panel discussion		巫錫霖 醫師 彰化秀傳
		東生華製藥股份有限公司 ROOM 402AB	
12:10-12:15	Opening		陳俊鴻 醫師 高醫附醫
12:15-12:35	Don't Wait to Intensify: Early Combination Lipid Management in Stroke Patients	郭曄嶸 醫師 亞東醫院	陳俊鴻 醫師 高醫附醫
12:35-12:45	Discussion		陳俊鴻 醫師 高醫附醫
12:45-13:05	Early Combination, Better Protection: Expanding ACEI + CCB Benefits in Post-Stroke Care	葉鎧境 醫師 新光醫院	張庭瑜 醫師 林口長庚
13:05-13:15	Discussion	張庭瑜 醫師 林口長庚	
13:15-13:30	Closing Remarks		連立明 醫師 新光醫院

NOV. 14 SAT.

TIME	TOPIC	SPEAKER	MODERATOR
		台灣禮來股份有限公司 ROOM 402C	
12:10-13:30	Manageable ARIA, Meaningful Outcomes: The clinical value of kisunla	蔡欣熹 醫師 台大醫院	宋碧姍 醫師 成大醫院
		台灣百靈佳殷格翰股份有限公司 ROOM 402D	
12:10-13:30	Metalyse 全新世代血栓溶解劑將為急性腦中風治療帶來什麼全新視野？	蔡力凱 醫師 台大醫院	陳　龍 醫師 雙和醫院
		賽諾菲股份有限公司 ROOM 403	
12:10-12:15	Opening		鍾芷萍 醫師 臺北榮總
12:15-12:45	The Benefits of Initiating DAPT in a Timely Manner for Patients with Minor Ischemic Stroke and TIA and Long-term Management	林浚仁 醫師 臺北榮總	鍾芷萍 醫師 臺北榮總
12:45-13:15	Striving for Improved Outcomes : LDL-C Reduction in Secondary Stroke Prevention	黃彥筑 醫師 嘉義長庚	陳右緯 醫師 聯新醫院
13:15-13:25	Discussion	All	
13:25-13:30	Closing Remarks		陳右緯 醫師 聯新醫院

午餐議程

NOV. 15 SUN.

TIME	TOPIC	SPEAKER	MODERATOR
		台灣拜耳股份有限公司 Venue 301	
12:00-12:05	Opening		陳　龍 醫師 雙和醫院
12:05-12:40	The First-in-Class nsMRA in DKD: A Deep Dive into the Clinical Evidence	蔡欣熹 醫師 台大醫院	陳　龍 醫師 雙和醫院
12:40-13:15	From Evidence to Action: How I Manage DKD Patients in Clinical Practice	黃道民 醫師 台大醫院	李怡慧 醫師 臺北榮總
13:15-13:25	Audience Q&A	All	
13:25-13:30	Closing		李怡慧 醫師 臺北榮總
		暉致醫藥股份有限公司 Main Hall (401)	
12:00-12:05	Opening		連立明 醫師 新光醫院
12:05-12:45	Lipid Management After Ischemic Stroke: When to Start, How Intensive, and How Low to Go?	劉濟弘 醫師 林口長庚	連立明 醫師 新光醫院
12:45-13:15	Case sharing	王淳民 醫師 成大醫院	楊浚銘 醫師 奇美醫院
13:15-13:25	Pannel Discussion	All	
13:25-13:30	Closing		楊浚銘 醫師 奇美醫院

NOV. 15 SUN.

TIME	TOPIC	SPEAKER	MODERATOR
		衛采製藥股份有限公司 ROOM 402C	
12:10-12:15	Opening		
12:15-13:00	From Amyloid Clearance to Sustained Clinical Benefit: Clinical and Real-World Evidence Supporting Continuous Treatment with Lecanemab	宋碧姍 醫師 成大醫院	胡朝榮 醫師 雙和醫院
13:00-13:10	Discussion and Closing		
		安沛國際有限公司 ROOM 402D	
12:00-12:10	Opening		
12:10-12:50	Tirofiban in Acute Ischemic Stroke : From Evidence to Bedside Decisions (Tirofiban在急性缺血性中風的應用：從實證醫學到臨床決策)	陳志昊 醫師 台大醫院	鄭建興 醫師 台大醫院
12:50-13:00	Discussion and Closing		
		台灣諾華股份有限公司 ROOM 403	
12:00-12:10	Opening		蔡力凱 醫師 台大醫院
12:10-12:45	From Plaque Burden to Risk Management : Why Earlier and Deeper LDL-C Lowering Matters	何明昀 醫師 林口長庚	
12:45-13:20	How Low Should We Go? LDL-C Management After Ischemic Stroke	黃彥筑 醫師 嘉義長庚	
13:20-13:30	Discussion & Closing		



Game changer:
Factor XI Inhibitors for Secondary Prevention of Non-Cardioembolic Ischemic Stroke

Mike Sharma / Canada
MD, MSC, FRCPC
Professor of Neurology, McMaster University
Neurologist, Hamilton Health Sciences
Senior Scientist, Population Health Research Institute

11/14 SAT. | 11:00-11:40 **Main Hall 401**

Executive Summary

Dr. Mike Sharma, MD, MSc, FRCPC, is a Professor, Medicine and holds the Michael G DeGroote Chair in Stroke Prevention, at McMaster University, is the Director of the Stroke Program at McMaster University and Hamilton Health Sciences, and is a Scientist at the Population Health Research Institute, Hamilton, ON, Canada. His research interests include the development of new antithrombotic treatments, incorporating magnetic resonance imaging endpoints into the design of stroke prevention trials and examining the effects of anticoagulants on stroke recurrence and covert brain infarcts. He has led trials and sub-studies in large prevention trials focused on these areas including COMPASS MIND (NCT03766581), NAVIGATE ESUS (NCT02313909), DATAS II (NCT02295826), AXIOMATIC-SSP (NCT03766581) and currently leads as co-principal investigator, the global phase III OCEANIC-STROKE (NCT05686070) trial investigating FXIa inhibition for stroke prevention in 36 countries. He is the immediate past Chair of the Canadian Stroke Consortium, the professional organization for stroke physicians and clinical trialists in Canada and established the stroke program at the University of Ottawa. Dr. Sharma is committed to developing integrated processes for stroke care and developing human and system capacity for the next generation of stroke trials.



Cerebral Small Vessel Disease: Recent Advances and Implications for Treatment

Joanna Wardlaw / United Kingdom
MD, FRCR, FMedSci, FRSE, CBE
Professor of Applied Neuroimaging, Director Row Fogo Centre for Research into Small Vessel Diseases, , University of Edinburgh
Foundation Chair, Clinical Co-Director UK Dementia Research Institute Centre for Vascular Dementia Research , UK Dementia Research Institute

11/14 SAT. | 15:30-16:10 **Main Hall 401**

Lecture Abstract

This lecture will cover recent information about cerebral small vessel disease including insights into the mechanisms and pathology, on small vessel lesions that are visible on brain imaging and how these relate to underlying tissue changes in apparently normal appearing tissue and abnormal tissue, the effect of visible lesions on remote brain regions, the underlying patterns of vascular dysfunction including blood-brain barrier dysfunction and glymphatic waste clearance, and the relationship to cognitive decline and other adverse clinical outcomes. It will also address current knowledge of prevention and treatment of cerebral small vessel disease including ongoing clinical trials testing novel compounds. The data will be from studies in patients and community dwelling volunteers and largely derive from studies using advanced brain and vascular imaging techniques paired with experimental medicine, cognitive, functional and blood biomarker assessments.



CADASIL as a Prototype for Precision Clinical Trials in Cerebral Small Vessel Disease

Hugues Chabriat / France

MD, PhD

Professor of Neurology, Université Paris Cité

Chair of the Translational Neurovascular Centre and Coordinator of the French Centre for rare cerebrovascular diseases , Hopital Lariboisiére, Assistance Publique des Hôpitaux de Paris (APHP)

Co-Head of the Research Team GENOVASC, INSERM U1127 and Paris Brain Institute

11/14 SAT. | 16:10-16:50 **Main Hall 401**

Lecture Abstract

CADASIL as a Prototype for Precision Clinical Trials in Cerebral Small Vessel Disease

CADASIL provides a particularly informative model for rethinking clinical trials in cerebral small vessel disease (CSVD). As a monogenic disorder with a relatively homogeneous underlying cause, it offers a setting in which disease mechanisms, biomarkers, prognostic markers, and treatment effects can be studied with greater precision than in the more heterogeneous forms of sporadic CSVD.

The ability to capture disease progression over relatively short time frames across several clinical and imaging domains will be discussed, including incident stroke, disability, cognition, brain atrophy, white matter hyperintensities, lacunes, and diffusion MRI abnormalities. Attention will be given to the relative sensitivity of these outcomes, as MRI-based measures appear more responsive to change than cognitive endpoints, which generally evolve more slowly and may require larger samples and longer follow-up to demonstrate treatment effects.

The potential contribution of brain imaging to prognostic enrichment and risk stratification will also be considered. Baseline lesion burden, diffusion abnormalities, brain atrophy, and other MRI markers associated with subsequent progression may help identify participants most likely to experience measurable change during the course of a trial. Mechanistic vascular endpoints, including cerebrovascular reactivity, cerebral blood flow, arterial stiffness, and advanced MRI measures, may also become potential markers associated with disease progression.

Finally, the value of broadening trial assessment beyond imaging and clinician-rated measures will be discussed. Patient-reported outcomes may capture important dimensions of disease, including fatigue, cognitive slowing, memory difficulties, gait impairment, motor symptoms, and emotional burden, which are not always adequately represented by standard outcome measures. Taken together, these different approaches suggest that CADASIL may serve as a prototype for more precise and efficient CSVD trials, combining genetic enrichment, prognostic stratification, multimodal imaging, vascular physiology, and patient-centered outcomes.



Endovascular thrombectomy - state of the art in 2026

Bernard Yan / Australia
Professor
Professor of Neurology, University of Melbourne

11/15 SUN. | 10:30-11:10 **Main Hall 401**

Lecture Abstract

Endovascular thrombectomy has transformed the treatment of large vessel occlusion stroke, but the “ideal” case, large vessel occlusion, small core and early presentation, now represents a shrinking share of the patients we treat. This lecture reviews how the evidence has moved from the foundational randomised trials of 2015 and the late-window trials of 2018, which underpinned the 2019 guidelines, to the 2026 American Stroke Association guideline, and examines what has driven those changes: intravenous thrombolytics alongside thrombectomy, large ischaemic core, and medium vessel occlusion.
Guidelines are, by nature, provisional: in a rapidly evolving field, new trials can overturn recommendations within months. I will discuss the first positive randomised trial of thrombectomy for medium vessel occlusion, followed by newly published positive late-window thrombectomy trial and the individual patient data analyses of the large-core trials. I will then describe how these findings are being applied in current clinical practice, including patient selection, imaging, and the balance between benefit and futility.
Finally, I will look at ongoing trials that may reshape the next guideline: ongoing late window trials, second-generation trials for medium vessel occlusion, and technology aimed at breaking the barrier of distance, including remote-controlled robotic thrombectomy. Attendees will leave with a framework for interpreting new evidence, an understanding of why today’s recommendations may not last, and a view of where thrombectomy is heading.

壁報論文總覽

01 特優

台灣腦中風學會優秀論文獎

紀乃方｜臺北榮民總醫院

血壓變異，腦血流自動調節，腦小血管疾病，以及認知功能的交互作用。
Interactions between blood pressure variability, cerebral autoregulation, and covert cerebral small vessel disease in relation to cognitive performance in community-dwelling older adults

02 特優

台灣腦中風學會優秀論文獎

王淳民｜國立成功大學醫學院附設醫院

整合式 drip-and-ship 模式改善腦中風轉診效率與預後：
與傳統 drip-and-ship 及mothership模式之比較
Integrated drip-and-ship improves stroke transfer efficiency and outcomes: a comparison with traditional drip-and-ship and mothership models

03 優等

台灣腦中風學會優秀論文獎

王胤丞｜臺北榮民總醫院

探討臺灣年輕型缺血性中風的新穎基因風險位點
Identification of Novel Genetic Risk Variants Associated With Early-Onset Ischemic Stroke in Taiwan

04 優等

台灣腦中風學會優秀論文獎

林育瑞｜臺北榮民總醫院

VasCog-2-WSO VCID 標準於無失智及無中風社區族群之驗證：心血管風險與死亡率
Validation of the VasCog-2-WSO VCID Criteria in a Dementia-Free and Stroke-Free Community Cohort: Cardiovascular Risk and Mortality

05 佳作

台灣腦中風學會優秀論文獎

嚴寶勝｜光田綜合醫院

在 70 歲以上急性缺血性腦中風患者中，年齡對取栓術後的功能預後預測效力有限：一項單中心世代研究
Age Demonstrates Limited Predictive Utility for Functional Outcomes After Thrombectomy in Patients Aged ≥70 Years With Acute Ischemic Stroke: A Single-Center Cohort Study

06 佳作

台灣腦中風學會優秀論文獎

呂冠嫻｜奇美醫院

導管消融與新診斷高風險心房顫動患者主要心血管不良事件風險之關聯：目標試驗模擬研究
Catheter ablation and risk of major adverse cardiovascular events in high-risk patients with newly diagnosed atrial fibrillation: a target trial emulation

07 台灣腦中風學會優秀論文獎

佳作

沈英琪｜台大醫院癌醫中心

NOTCH3 小血管病變之疾病分期對 NOTCH3 p.R544C 變異的預後意義
Prognostic Significance of NOTCH3 Small Vessel Disease Staging for the NOTCH3 p.R544C Variant

08 台灣腦中風學會優秀論文獎

佳作

陳敏碩｜林口長庚紀念醫院

放射線治療後頸總動脈狹窄之超音波診斷效能：一項橫斷面驗證研究
Diagnostic Performance of Duplex Ultrasonography in Post-Radiation Common Carotid Artery Stenosis

09 台灣腦中風學會優秀論文獎

佳作

歐陽彣昱｜臺北榮民總醫院

前顳葉白質高訊號病灶在 CADASIL 與非遺傳性腦小血管疾病中的診斷價值與臨床意義
Diagnostic Value and Clinical Significance of Temporopolar White-Matter Hyperintensities in CADASIL and Sporadic Small-Vessel Disease

10 台灣腦中風學會優秀論文獎

佳作

蔡穩穩｜奇美醫院

急性缺血性中風於 4.5 小時後影像灌流導引的溶栓治療：依時間分層之系統性回顧與統合分析
Perfusion-guided thrombolysis beyond 4.5 hours for acute ischemic stroke: A time-stratified systematic review and meta-analysis

11 腦血管疾病防治基金會高明見教授優秀論文獎

第一名

劉兆禹｜台大醫院

腦部微出血作為 NOTCH3 R544C CADASIL 臨床預後之獨立預測因子
Cerebral Microbleed Burden as an independent Predictor of Clinical Outcomes in NOTCH3 R544C CADASIL

12 腦血管疾病防治基金會高明見教授優秀論文獎

第二名

謝秉辰｜台大醫院

多相電腦斷層血管攝影點狀徵象（spot sign）對自發性腦內出血患者預後之預測價值
Prognostic Value of the Multiphase CT Angiography Spot Sign in Spontaneous Intracerebral Hemorrhage

壁報論文總覽

13

日新紀念論文獎

論文獎

周鴻杰｜彰化基督教醫院

動脈取栓於腦中小血管阻塞之效益：統合分析
Thrombectomy for Distal Medium Vessel Occlusion: A Meta-Analysis of Randomized Controlled Trials

14

杜世彬博士紀念論文獎

第一名

許紹倫｜天主教輔仁大學附設醫院

影像評估之腦部年齡與 CADASIL 疾病嚴重度及不良預後之關聯性
Association of imaging-defined brain age with disease severity and adverse outcomes in CADASIL

15

杜世彬博士紀念論文獎

第二名

王其聖｜臺中榮民總醫院

遠距視訊會診改善偏鄉腦中風轉診效率與功能性預後：一個回溯性世代追蹤研究
Video-Conferencing Teleconsultation Improves Transfer Efficiency and Functional Outcomes in Rural Stroke Care: Retrospective Cohort Study

16

杜世彬博士紀念論文獎

第三名

石宇辰｜台大醫院

大腦類澱粉血管病變相關腦出血之亞洲族群電腦斷層診斷準則：磁振造影與病理驗證
Asian CT Criteria for Cerebral Amyloid Angiopathy-related Intracerebral Hemorrhage: MRI and pathology Validations

17

杜嘉慧｜花蓮慈濟醫院

神經精神性系統性紅斑狼瘡表現為復發性中風樣症狀
Neuropsychiatric Systemic Lupus Erythematosus Presenting as Recurrent Stroke Mimics

18

柯麗櫻｜台中光田醫院

破裂性顱內動脈瘤栓塞併發血栓之救援性支架取栓術：病例報告
Rescue mechanical thrombectomy using a retrievable stent for thromboembolic occlusion occurring during coil embolization of ruptured intracranial aneurysm: A case report.

19

陳宇澤｜雙和醫院

人工智慧輔助非顯影電腦斷層於急性缺血性腦中風大血管阻塞偵測之診斷效能
Diagnostic Performance of AI-Assisted Non-Contrast CT for Large Vessel Occlusion Detection in Acute Ischemic Stroke

優秀壁報

20

王淳民｜國立成功大學醫學院附設醫院

急性腦中風後的多重預後面向與台灣本土健康效用值：從 mRS 之外看見的失能全貌
Beyond the Modified Rankin Scale: Multidimensional Outcomes and Taiwan-Specific Health Utility After Acute Stroke

優秀壁報

21

黃詠昀｜台大醫院

早期認知障礙患者之腦類澱粉血管病變：Boston Criteria 不同版本之比較與認知影響
Cerebral amyloid angiopathy in early cognitive impairment: comparisons between versions of the Boston criteria and cognitive impact

22

李依鴻｜高雄醫學大學附設中和紀念醫院

建構吞嚥障礙個案管理模式對神經科病人臨床與永續效益之成效： 回溯性世代研究
Clinical and Sustainable Impacts of a Specialized Dysphagia Nurse Case Management Model in Neurological Patients: A Retrospective Cohort Study

23

王偉昇｜彰化秀傳紀念醫院

非創傷性熊貓眼：顱內腫塊效應的神經學警示徵象
Nontraumatic Raccoon Eyes as a Neurologic Warning Sign of Intracranial Mass Effect

優秀壁報

24

黃蕙琦｜臺北榮民總醫院護理部

缺血性中風合併低密度膽固醇≤ 55 mg/dL 患者一年功能預後研究
1-year functional outcomes in ischemic stroke patients with LDL-C ≤ 55 mg/dl

壁報論文總覽

25

黃玉雰｜高雄醫學大學附設中和紀念醫院護理部

臨床專業人員主導、人工智慧輔助之腦中風病人個人化居家復健衛教模式：聚焦式文獻回顧
A Clinician-Led, AI-Assisted Model for Personalized Home Rehabilitation Education After Stroke: A Focused Literature Review

26

鄭宗敏｜台大流行病學與預防醫學研究所

口服抗凝藥物相關腦出血的反轉劑治療的預後
Outcomes of Reversal Agents Use for Oral Anticoagulant-Associated Intracerebral Hemorrhage

27 優秀壁報



陳奕翔｜基隆長庚紀念醫院

顱內動脈粥狀硬化狹窄的「慢速進展者」表現型可預測動脈內取栓手術複雜度與復原軌跡
The "Slow-Progressor" Phenotype in ICAD Predicts Procedural Complexity and Recovery Trajectories Following Endovascular Thrombectomy

28 優秀壁報



鄭博嘉｜國立成功大學醫學院附設醫院神經部

台灣中風發生率及其決定因子之全國性貝氏時空分析（2007–2021年）
A Nationwide Bayesian Spatiotemporal Analysis of Stroke Incidence and Its Determinants in Taiwan, 2007-2021

29

林冠宏｜奇美醫院

以入院評估資料預測中風住院病人之院內肺炎
Predicting Hospital-Acquired Pneumonia in Hospitalized Stroke Patients Using Admission Assessment Data

30

陳志昊｜台大醫院

根據 RESCUE BT2 試驗亞族群給予Tirofiban的安全與臨床結果：台灣多中心登錄研究
Safety and Clinical Outcomes of Tirofiban Across RESCUE BT2 Indication Subtypes: A Taiwan Multi-Center Registry

31

戴韶廷｜台大醫院

復發性腦梗塞於 Emery-Dreifuss 肌肉失養症與抗磷脂質症候群之年輕女性：病例報告
Recurrent Ischemic Stroke in a Young Woman with Coexisting LMNA-Related Emery-Dreifuss Muscular Dystrophy and Antiphospholipid Syndrome

32

葉育雯｜臺北榮民總醫院

比較手持式超音波（Lumify/Apach）與傳統式超音波（EPIQ7）在腦內血管偵測的應用
Comparison of POCUS (Lumify / Apach) vs. EPIQ7 for Intracranial Vessel Detection

33

賴樂燕｜衛生福利部雙和醫院

「五個自動」打造腦中風高血脂智慧管理：門診自動收案流程之建置與應用
"Five Automations" for Smart Lipid Management in Secondary Stroke Prevention: Development and Implementation of an Automated Outpatient Enrollment Workflow

34 優秀壁報

賴樂燕｜衛生福利部雙和醫院

智慧自動收案導入後腦中風高血脂管理成效：降血脂 治療介入與 LDL-C 改善分析
Lipid Management Outcomes After Implementation of Automatic Enrollment System for Secondary Stroke Prevention: Lipid-Lowering Therapy and LDL-C Changes

35

謝沛峰｜台大醫院新竹分院

血漿 pTau-217 在腦部類澱粉血管病變中預測出血及死亡
Plasma Phosphorylated Tau 217 Predicts Longitudinal Macrohemorrhage and Mortality in Cerebral Amyloid Angiopathy

36

林珮如｜聯新國際醫院

建構智慧醫療轉診模式於急性腦中風取栓治療時效及預後改善之成效探討
Effectiveness of Constructing an Intelligent Healthcare Referral Model in Improving Treatment Timeliness and Clinical Outcomes of Endovascular Thrombectomy in Acute Ischemic Stroke

壁報論文總覽

37 優秀壁報



林宜靜｜台北馬偕醫院

未通過急性缺血性中風後床邊吞嚥篩檢：五年醫院中風登錄資料之預測因子與住院預後分析
Failed Bedside Swallowing Screening After Acute Ischemic Stroke: Predictors and In-Hospital Outcomes in a 5-Year Hospital Stroke Registry

38

何柏陵｜高雄醫學大學附設中和紀念醫院

惡性中大腦動脈梗塞與功能性預後：回溯性世代研究
Malignant Middle Cerebral Artery Infarction and Functional Outcome: A Retrospective Cohort Study

39

蔡穩穩｜奇美醫院

COVID-19 相關腦中風之抗栓治療選擇：重症肝硬化患者的臨床困境
Anticoagulation versus Antiplatelet Therapy in COVID-19–Related Stroke: Navigating Clinical Dilemmas in a Critically Ill Cirrhotic Patient

40

林欣儀｜台大醫院

心房顫動合併低直接口服抗凝血劑濃度之急性缺血性中風病人接受靜脈血栓溶解治療的療效與安全性
Safety and Outcomes of Intravenous Alteplase in Patients with Atrial Fibrillation and Low Plasma Direct Oral Anticoagulant Concentrations

41 優秀壁報



陳柏霖｜台中榮民總醫院

延遲口服抗凝血劑使用時機與心房顫動相關腦中風的較低良好預後機會相關
Delayed Onset-to-OAC Time is Associated with a Lower Probability of Favorable Outcome in AF-Related AIS

42

李湘婷｜臺北醫學大學附設醫院

從出院到追蹤：以 EQ-5D-5L 建立腦中風病人報告結果追蹤機制
From Discharge to Follow-Up: Establishing a Post-Stroke Patient-Reported Outcomes Tracking System Using EQ-5D-5L

43

林美伶｜大林慈濟醫院(護理部、品管中心、中風中心)

透過資訊系統支持提升急性中風護理遵從性
Enhancing Acute Stroke Care Adherence Through Information System Support

44

林英妙｜聯新國際醫院個案管理師處

住院接受中醫輔助醫療之腦中風病人出院後一年失能程度之縱向變化：
改良式 Rankin 量表分析
One-Year Longitudinal Changes in Disability Among Hospitalized Stroke Patients Receiving Integrative Traditional Chinese Medicine: A Modified Rankin Scale Analysis

45

陳致霖｜彰濱秀傳紀念醫院

電腦斷層"極度高密度血管徵"：栓塞或顱內動脈粥狀硬化？一個急性腦中風的個案報告。
Extreme Hyperdensity of an Occluded Middle Cerebral Artery Mimicking Intracranial Atherosclerotic Disease: A Pathologically Proven Calcified Thrombus

46 優秀壁報

吳宛蓉｜台大醫院

透過流程改善縮短急性缺血性腦中風之到院至給藥時間：單一中心前後對照研究
Reducing Door-to-Needle Time Through Workflow Optimization in Acute Ischemic Stroke Care: A Single-Center Before-and-After Study

47

郭品言｜台大醫院

皮質內大葉型微出血與腦出血復發風險增加之關聯
Intracortical lobar cerebral microbleeds predict higher risk of recurrence in intracerebral hemorrhage survivors

48

陳怡君｜聯新國際醫院

導入智慧化電子轉銜系統優化急性腦中風急性後期照護（PAC）評估流程之成效
Streamlining Post-Acute Care (PAC) Transfer Assessment for Acute Stroke Patients via Electronic Workflow: An Interdisciplinary Process Optimization

壁報論文總覽

49 優秀壁報

鄭宗敏｜台大流行病學與預防醫學研究所

整合臨床特徵和多基因風險評分預測中風後失智：群體世代研究
Integrating Clinical Profiles and Polygenic Risk Scores to Predict Post-Stroke Dementia: A Population-Based Cohort Study

50

許芝菱｜台北榮民總醫院

年輕型腦中風以多領域認知功能障礙為表現：頂葉－胼胝體網絡分離症候群
Young-Onset Stroke Presenting as Multidomain Cognitive Impairment: A Parieto-Callosal Disconnection Syndrome

51 優秀壁報

林聖傑｜衛生福利部雙和醫院

日本與台灣兩中心急性缺血性腦中風血管內血栓移除術之治療流程與臨床結果比較
Endovascular Thrombectomy in Japan and Taiwan: A Two-Center Real-World Comparison of Workflow and Outcomes

52

邱景暉｜臺北市立萬芳醫院

使用鈉－葡萄糖共同轉運蛋白2抑制劑之急性缺血性腦中風患者於血管內血栓移除術後發生正常血糖型糖尿病酮酸中毒：兩例病例報告
Euglycemic Diabetic Ketoacidosis Following Endovascular Thrombectomy for Acute Ischemic Stroke in Patients Receiving Sodium–Glucose Cotransporter-2 Inhibitors: A Report of Two Cases

53 優秀壁報

張陳臻｜台大醫院

腦出血合併混合型腦微出血患者中 NOTCH3 基因變異與非基因變異者之臨床特徵及中風復發風險比較
Clinical Features and Stroke Recurrence in NOTCH3-Related and Non-Genetic Intracerebral Hemorrhage with Mixed-Location Cerebral Microbleeds

54 優秀壁報

楊茗臻｜林口長庚紀念醫院

無症狀重度放射性頸動脈狹窄於藥物治療下之中風風險
Stroke Risk and Medical Therapy for Asymptomatic Severe Radiation-Induced Carotid Stenosis in Head and Neck Cancer Patients

55

鄭博嘉｜國立成功大學醫學院附設醫院

CADASIL 與大腦類澱粉血管病變之腦出血：臨床特徵、神經影像及長期預後之比較
Intracerebral Hemorrhage in CADASIL and CAA: A Comparison of Clinical Features, Neuroimaging, and Long-Term Outcomes

56

駱怡潔｜高雄醫學大學附設中和紀念醫院

住院醫療整合照護暨急性後期照護轉銜於年輕型腦中風病人之成效：
長照3.0政策下之個案報告
Effectiveness of Integrated Inpatient Care and Post-Acute Care Transition in a Young Adult With Stroke: A Case Report Under Taiwan's Long-Term Care 3.0 Policy

57

陳佳琪｜台大醫院

出血型與非出血型大腦類澱粉血管病變的神經影像特徵與長期預後分析
Neuroimaging Biomarker Signatures and Long-Term Outcomes in Cerebral Amyloid Angiopathy With and Without Intracerebral Hemorrhage

58

林俐瑩｜林口長庚紀念醫院

Enoxaparin 治療非預期發現之頸動脈網合併血栓：病例報告
Incidentally Detected Carotid Web With Superimposed Thrombus: Rapid Regression After Enoxaparin

59 優秀壁報

李剛伯｜高雄秀傳紀念醫院神經內科

ANCHORS-AIS 模型的建立與時間性驗證：急性缺血性腦中風後多時間窗死亡風險預測
Beyond Stroke Severity: Development and Temporal Validation of the ANCHORS-AIS Model for Multi-Horizon Mortality Prediction After Acute Ischemic Stroke

60

陳奕翔｜基隆長庚紀念醫院

成功取栓的「黃金一小時」：
60分鐘手術時間閾值預測前循環大血管阻塞患者的症狀性顱內出血
The "Golden Hour" of Successful Thrombectomy: A 60-Minute Procedural Threshold Predicts Symptomatic Intracranial Hemorrhage in Anterior Circulation Large Vessel Occlusion

壁報論文總覽

61

陳奕翔｜基隆長庚紀念醫院

運用血管阻塞部位與電腦斷層灌流資料之機器學習模型區分心因性栓塞與顱內動脈粥狀硬化疾病
Machine Learning-Based Differentiation of Cardioembolism and Intracranial Atherosclerotic Disease Using Occlusion Site and Computed Tomography Perfusion Data

優秀壁報

62



呂冠嫻｜奇美醫院

「智腦先風」於急性中風影像登錄之應用：結構化資料擷取之30例先導驗證
Large Language Model–Based Structured Data Extractionfor an Acute Stroke Imaging Registry: A Pilot Validation in 30 Consecutive Cases

63

蔡覺毅｜中山醫學大學附設醫院

Lecanemab 治療期間急性大血管阻塞之直接血管內取栓：病例報告
Direct Endovascular Thrombectomy for Acute Large-Vessel Occlusion During Lecanemab Therapy: A Case Report

優秀壁報

64




郭馥瑄｜台中榮民總醫院

覆膜支架重建術單獨或合併外頸動脈栓塞治療頸動脈爆裂症候群：單中心20例回溯性病例系列
Covered-Stent Reconstruction With or Without Adjunctive External Carotid Artery Embolization for Carotid Blowout Syndrome: A Single-Center Retrospective Case Series

Strengthen Secondary Prevention:

Protect Your Patients from Recurrent Ischemic Events



sanofi



Easy & Powerful Choice


高效能，一錠達標

VOYAGER Study

降低 LDL-C效果

CRESTOR 10 mg顯著優於atorvastatin 20 mg

CRESTOR 20 mg顯著優於atorvastatin 40 mg



Adapted from Karlson, Björn W., et al. *Am J Cardiol. 2016 May 1;117(9):1444-8.*

冠脂妥® 膜衣錠5、10、20毫克 CRESTOR® 5, 10, 20 mg Film-Coated Tablets

【適應症】高膽固醇血症：減少膽甘油酯血症（其他治療】CRESTOR有X型作用，請參閱完整內容。高膽固醇血症（異型家族子基因型及非家族型）：混合血脂異常血症（Fredrickson IIa及IIb型）：CRESTOR的開始劑量為5-20 mg每天一次，並應根據治療目標及個別病人的反應，而在適當時間作調整。CRESTOR 5 mg為起始劑量的病患，若預期在低劑量下達不到治療目標，例如：嚴重的cyclosporine病患，正在服用之其他藥物可能與CRESTOR產生交互作用，而且可能會增加肌病變風險（參閱警語與注意事項）。CRESTOR 10 mg為起始劑量的病患，若預期在低劑量下達不到治療目標，例如：嚴重的cyclosporine病患，正在服用之其他藥物可能與CRESTOR產生交互作用，而且可能會增加肌病變風險（參閱警語與注意事項）。CRESTOR 20

為每位病人找到合適劑量，
提供預防中風的
安心選擇[1-3]

MADE IN 德國 原裝進口 GERMANY



1. Giugliano RP, et al. N Engl J Med. 2013 Nov 28;369 (22):2093-104.
2. Okumura K, et al. N Engl J Med. 2020 Oct 29;383 (18):1735-1745.; 3. Chao TF, et al. JACC Asia. 2023 Oct 17; 3 (5):707-723.

* 排除標準：• 病人曾有嚴重心臟瓣膜疾病 • 14 天內發生中風，收案前的 6 個月內發生顱叢中風
• 有增加出血風險的情況，肌酐酐清除率小於 15 mL/min，或大於 95 mL/min，活動性肝病和懷孕

【禁忌】對本品活性成分或賦形劑過敏、臨床上有重大活動性出血、合併凝血功能障礙之肝臟疾病、高出血風險的病灶或病史、控制不良的嚴重高血壓，同時使用其他抗凝血劑、以及懷孕與哺乳期間。【警語】Lixiana® 15 mg 不適用於單一治療，僅限於自 30 mg 轉換至 VKA 過程中合併使用，或於 NVAF 病人中，依年齡及臨床狀況考量將劑量調整為每日一次 15 mg。使用 Lixiana® 會增加出血風險，且可能致命。對於高風險族群（如高齡患者或具有合併病史者）須密切監測出血及貧血狀況；若發生嚴重出血，應立即停藥。常規實驗室檢測（PT/INR/aPTT）無法可靠反應抗凝效果，且目前無專一解毒劑。血液透析亦無效。必要時可透過抗因子 Xa 檢測協助估算藥效。倘手術或介入治療時，建議於至少 24 小時前停藥；手術完成並復到止血後，應儘快恢復用藥。與影響止血之藥物併用（如阿斯匹靈（ASA）、P2Y12 抑制劑、其他抗血栓藥物、消炎治療、SSRI 或 SNRI 類抗憂鬱藥、長期使用之 NSAIDs）會增加出血風險。不建議使用於下列族群：機械性人工心瓣膜置患者、生物瓣置換術後三個月內（不論是否合併心房顫動）、以及中度至重度二尖瓣狹窄患者。曾有案例顯示抗凝劑相關腎病變（如急性腎損傷、血尿）。對於腎功能異常或出現血尿的病人，應加強監測。其他注意事項：Lixiana® 對駕駛及機械操作能力無明顯影響；抗凝血作用的於給藥後 1-2 小時發揮。
【副作用】常見副作用包括：流鼻血（7.7%）、血尿（6.9%）、貧血（5.3%）。

里先安® 膜衣錠
Lixiana® F.C. Tablets
電子仿單QR Code

60 mg 30 mg 15 mg

Daiichi-Sankyo
台灣第一三共股份有限公司 電話：(02)8772-2250
台北市松江路223號13樓 https://www.daiichisankyo.com.tw

once-daily Lixiana® edoxaban
里先安® 膜衣錠
60mg / 30mg / 15mg

衛部藥輸字第 026599 號 衛部藥輸字第 026600 號 衛部藥輸字第 026601 號 北市商廣廣字第 114120027 號 仿單請洽資料部更新版本

DSTW-LIX-05/2025-0017

